Federated Hermes Inc. Has $1.59 Million Stock Holdings in R1 RCM Inc. (NASDAQ:RCM)

Federated Hermes Inc. lifted its stake in R1 RCM Inc. (NASDAQ:RCM) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 150,556 shares of the healthcare provider’s stock after acquiring an additional 7,219 shares during the quarter. Federated Hermes Inc.’s holdings in R1 RCM were worth $1,591,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of RCM. Headlands Technologies LLC bought a new stake in R1 RCM during the third quarter worth $36,000. Van ECK Associates Corp increased its stake in shares of R1 RCM by 28.5% during the 3rd quarter. Van ECK Associates Corp now owns 5,097 shares of the healthcare provider’s stock worth $77,000 after purchasing an additional 1,130 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in shares of R1 RCM by 429.5% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock valued at $59,000 after purchasing an additional 4,561 shares during the period. Salem Investment Counselors Inc. acquired a new stake in R1 RCM in the 4th quarter valued at about $61,000. Finally, Fox Run Management L.L.C. bought a new position in R1 RCM during the third quarter worth about $189,000. Institutional investors own 61.10% of the company’s stock.

Insider Buying and Selling

In related news, President John M. Sparby sold 10,046 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $14.33, for a total transaction of $143,959.18. Following the completion of the sale, the president now owns 265,986 shares of the company’s stock, valued at $3,811,579.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 36.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Truist Financial restated a “hold” rating and issued a $16.00 price objective on shares of R1 RCM in a research note on Monday, April 1st. Canaccord Genuity Group cut their price target on R1 RCM from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, March 20th. Leerink Partnrs reiterated an “outperform” rating on shares of R1 RCM in a report on Monday, February 26th. Royal Bank of Canada reissued an “outperform” rating and issued a $19.00 price objective on shares of R1 RCM in a research report on Thursday, March 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $17.00 target price on shares of R1 RCM in a report on Tuesday, March 26th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.87.

R1 RCM Stock Performance

R1 RCM stock opened at $12.35 on Tuesday. The stock’s fifty day moving average price is $12.86 and its two-hundred day moving average price is $11.42. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.83 and a current ratio of 1.83. R1 RCM Inc. has a one year low of $8.87 and a one year high of $18.70.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.